APM
RVPH

Avidity Partners Management’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Avidity Partners Management’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,900
Closed -$52.6K – 61
2025
Q2 		$52.6K Hold
6,900
– – 0.01% 56
2025
Q1 		$132K Buy
+6,900
New +$217K 0.03% 67

Other funds holding RVPH

DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $225M AUM 25.8% 1-Year Est. Return

Avidity Partners Management's RVPH Position: Q3 2025 in Review

Avidity Partners Management sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2025, closing a stake of 6,900 shares — an estimated $52.6K sold.

Avidity Partners Management first reported a position in RVPH in Q1 2025 and held it in 2 quarters. The position peaked at $132K in Q1 2025. 42 funds tracked by Wall St. Rank hold RVPH as of Q3 2025.

  • Avidity Partners Management reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2025 after selling out during the quarter.
  • Avidity Partners Management sold 6,900 REVIVA PHARMA HLDGS INC shares in Q3 2025, an estimated $52.6K.
  • Avidity Partners Management first reported a position in REVIVA PHARMA HLDGS INC in Q1 2025 and held it in 2 quarters.
  • Avidity Partners Management's REVIVA PHARMA HLDGS INC position peaked at $132K in Q1 2025.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.